Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Puma Biotech Drug Patent Portfolio

Puma Biotech owns 1 orange book drug protected by 11 US patents Given below is the list of Puma Biotech's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8669273 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine 18 Jul, 2031
Active
US7399865 Protein tyrosine kinase enzyme inhibitors 29 Dec, 2030
Active
US8518446 Coated tablet formulations and uses thereof 20 Nov, 2030
Active
US8790708 Coated tablet formulations and uses thereof 05 Nov, 2030
Active
US9211291 Treatment regimen utilizing neratinib for breast cancer 24 Mar, 2030
Active
US9265784 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine 04 Aug, 2029
Active
US10035788 Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof 15 Oct, 2028
Active
US9139558 Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof 15 Oct, 2028
Active
US9630946 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof 15 Oct, 2028
Active
US7982043 Protein tyrosine kinase enzyme inhibitors 08 Oct, 2025
Active
US6288082 Substituted 3-cyanoquinolines 24 Sep, 2019 Expired


Given below is the list of recent legal activities going on the following drug patents of Puma Biotech.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 09 Aug, 2023 US9265784
Payment of Maintenance Fee, 8th Year, Large Entity 31 May, 2023 US9211291
Payment of Maintenance Fee, 8th Year, Large Entity 08 Mar, 2023 US9139558
Payment of Maintenance Fee, 12th Year, Large Entity 06 Jan, 2023 US7982043
Payment of Maintenance Fee, 4th Year, Large Entity 19 Jan, 2022 US10035788
Payment of Maintenance Fee, 8th Year, Large Entity 12 Jan, 2022 US8790708
Patent Term Extension Certificate
Critical
19 Nov, 2021 US7399865
Change in Power of Attorney (May Include Associate POA)
Critical
04 Oct, 2021 US7399865
Email Notification
Critical
04 Oct, 2021 US7399865
Correspondence Address Change
Critical
03 Oct, 2021 US7399865
Payment of Maintenance Fee, 8th Year, Large Entity 25 Aug, 2021 US8669273
Notice of Final Determination -Election Required 22 Feb, 2021 US7399865
Notice of Final Determination -Election Required 22 Feb, 2021 US9211291
Payment of Maintenance Fee, 8th Year, Large Entity 10 Feb, 2021 US8518446
Payment of Maintenance Fee, 4th Year, Large Entity 24 Sep, 2020 US9630946


Puma Biotech Drug Patents' Oppositions Filed in EPO

Puma Biotech drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 03, 2016, by Hexal Ag. This opposition was filed on patent number EP10722215A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP10779339A May, 2020 Cooke, Richard Patent maintained as amended
EP09791127A Oct, 2017 Hexal AG Granted and Under Opposition
EP10722215A Aug, 2016 Hexal AG Revoked


Puma Biotech's Family Patents

Puma Biotech drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 13.1% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Puma Biotech Drug List

Given below is the complete list of Puma Biotech's drugs and the patents protecting them.


1. Nerlynx

Nerlynx is protected by 11 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8669273 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine 18 Jul, 2031
(6 years from now)
Active
US7399865 Protein tyrosine kinase enzyme inhibitors 29 Dec, 2030
(6 years from now)
Active
US8518446 Coated tablet formulations and uses thereof 20 Nov, 2030
(5 years from now)
Active
US8790708 Coated tablet formulations and uses thereof 05 Nov, 2030
(5 years from now)
Active
US9211291 Treatment regimen utilizing neratinib for breast cancer 24 Mar, 2030
(5 years from now)
Active
US9265784 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine 04 Aug, 2029
(4 years from now)
Active
US10035788 Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof 15 Oct, 2028
(3 years from now)
Active
US9139558 Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof 15 Oct, 2028
(3 years from now)
Active
US9630946 Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof 15 Oct, 2028
(3 years from now)
Active
US7982043 Protein tyrosine kinase enzyme inhibitors 08 Oct, 2025
(9 months from now)
Active
US6288082 Substituted 3-cyanoquinolines 24 Sep, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nerlynx's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List